KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesAmortizatization of IntangiblesAmortizatization of IntangiblesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresLong-Term Debt IssuancesNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ClearPoint Neuro (CLPT) Gains from Sales and Divestitures (2018 - 2026)

ClearPoint Neuro recorded quarterly Gains from Sales and Divestitures of $748681.0 in Q1 2026, up 20.66% quarter-over-quarter from $620493.0 in Q4 2025, and up 5660.86% year-over-year from $12996.0 in Q1 2025.

ClearPoint Neuro's Gains from Sales and Divestitures history runs 7 years deep, the most recent figure standing at $748681.0 for Q1 2026.

  • In Q1 2026, Gains from Sales and Divestitures rose 5660.86% year-over-year to $748681.0; the TTM figure through Mar 2026 stood at $748681.0 (up 5660.86% YoY), while the FY2025 annual figure was $620493.0, up 129.24% from the prior year.
  • Gains from Sales and Divestitures came in at $748681.0 for Q1 2026 at ClearPoint Neuro, up from $620493.0 in the prior quarter.
  • In the past five years, Gains from Sales and Divestitures ranged from a high of $748681.0 in Q1 2026 to a low of $12996.0 in Q1 2025.
  • A 3-year average of $399915.8 and a median of $443945.5 in 2024 frame the typical range for Gains from Sales and Divestitures.
  • Across the five-year window, Gains from Sales and Divestitures soared 129.24% in 2025 and soared 5660.86% in 2026, its largest moves.
  • ClearPoint Neuro's Gains from Sales and Divestitures stood at $270673.0 in 2024, then jumped by 129.24% to $620493.0 in 2025, then rose by 20.66% to $748681.0 in 2026.
  • According to Business Quant data, Gains from Sales and Divestitures over the past three periods registered $748681.0, $620493.0, and $617218.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Abbott Laboratories 152.82 Bn 146.17 Bn 6.27 Bn
2 Stryker 115.07 Bn 112.19 Bn 3.81 Bn
3 Medtronic 95.25 Bn 87.08 Bn 5.76 Bn
4 Boston Scientific 71.38 Bn 70.17 Bn 3.61 Bn
5 Edwards Lifesciences 51.08 Bn 47.41 Bn 1.29 Bn
6 Koninklijke Philips 29.38 Bn 26.07 Bn 2.07 Bn
7 Dexcom 28.84 Bn 27.72 Bn 750.30 Mn
8 GE HealthCare Technologies 28.56 Bn 26.49 Bn 1.98 Bn
9 Steris 20.71 Bn 20.30 Bn 697.10 Mn
10 ClearPoint Neuro 375.84 Mn 340.24 Mn 7.76 Mn

Historic Data

Download Data 🔒
DateValue
Mar 31, 2026 748,681.00
Mar 31, 2026 748,681.00
Dec 31, 2025 620,493.00
Dec 31, 2025 620,493.00
Sep 30, 2025 617,218.00
Sep 30, 2025 617,218.00
Jun 30, 2025 129,434.00
Jun 30, 2025 129,434.00
Mar 31, 2025 12,996.00
Mar 31, 2025 12,996.00
Dec 31, 2024 270,673.00
Dec 31, 2024 270,673.00
Sep 30, 2021 2.02 Mn
Sep 30, 2021 2.02 Mn
Jun 30, 2021 1.59 Mn
Jun 30, 2021 1.59 Mn
Mar 31, 2021 1.15 Mn
Mar 31, 2021 1.15 Mn
Dec 31, 2020 2.16 Mn
Dec 31, 2020 2.16 Mn
Sep 30, 2020 625,407.00
Sep 30, 2020 625,407.00
Jun 30, 2020 428,532.00
Jun 30, 2020 428,532.00
Mar 31, 2020 427,657.00
Mar 31, 2020 427,657.00
Dec 31, 2019 2.93 Mn
Dec 31, 2019 2.93 Mn
Dec 31, 2018 221,773.00
Dec 31, 2018 221,773.00